Market Size (2018)
2018
$565.20M
Healthcare
Breast Biopsy Market
By Segment, By Region, And Segment Forecasts, 2018 – 2030
Vertical: HealthcareBase Year: 202112 Sections
Executive Summary
Breast Biopsy Market — Snapshot
Projected (2030)
2030
$1.19B
CAGR (2018–2030)
6.4%
6.4%Key Players
106+
This report covers Breast Biopsy Market with forecasts from 2018 to 2030. 106 key companies are profiled.
Key Insight
The Breast Biopsy Market market is projected to grow at a CAGR of 6.4% from 2018 to 2030.
Market Performance Trend
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Scope & Coverage
What this report covers
- Geographic Coverage: This analysis covers 4 regions: North America, Europe, Asia Pacific, Rest of the World.
- Market Segmentation: The market is analyzed across 5 segments: Biopsy Needles, Biopsy Wires, Guidance Systems, Others, Biopsy Tables. Forecasts are provided for each segment from 2018 to 2030.
- Competitive Landscape: 106 leading companies are profiled, covering market positioning, strategies, and recent developments.
Market Size (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Overview
Breast Biopsy Market — Growth Trajectory
A breast biopsy is a procedure to remove a sample of breast tissue for testing. The tissue sample is sent to a lab, where doctors who specialize in analyzing blood and body tissue (pathologists) examine the tissue sample and provide a diagnosis.
Breast Biopsy Market — Growth Trajectory
Biopsy Needles
Biopsy Wires
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Size Trend (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Dimensions
How this market is segmented
- By Product Type By Product Type is broken down into: Biopsy Needles, Biopsy Tables, Biopsy Wires, Guidance Systems, Others.
- By Technique By Technique is broken down into: Fine Needle Aspiration Biopsy, Core Needle Biopsy, Biopsy Marker, MRI-Guided Core Needle Biopsy, Surgical Biopsy, Wire Localization, Sentinel Node Biopsy.
- By Guidance Technology By Guidance Technology is broken down into: Ultrasound-Guided, Mammography-Guided Magnetic Resonance, CT-Guided Biopsy, Other Image-Guided Breast Biopsy (PET and thermography).
- By End User By End User is broken down into: Hospitals & Clinics, Diagnostic & Imaging Centers, Academic & Research Institutes, By End User_Others.
Geographic Analysis
Regional market breakdown
- North America North America market size reached $202.80M in 2018 and is projected to reach $406.60M by 2030, growing at a CAGR of 6.0%.
- Europe Europe market size reached $148.90M in 2018 and is projected to reach $303.90M by 2030, growing at a CAGR of 6.1%.
- Asia Pacific Asia Pacific market size reached $158.70M in 2018 and is projected to reach $376.50M by 2030, growing at a CAGR of 7.5%.
- Rest of the World Rest of the World market size reached $54.80M in 2018 and is projected to reach $98.70M by 2030, growing at a CAGR of 5.0%.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansResearch Methodology
Breast Biopsy Market — How We Researched This Market
This report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2021
Historical Period
2018 – 2021
Forecast Period
2021 – 2030
Primary Interviews
150+
Research Process
Historical data (2018–2021) and forecast period (2021–2030)
1
Problem Definition
- Market scoping
- Objective setting
- Framework design
2
Secondary Research
- Literature review
- Data mining
- Trend analysis
3
Primary Research
- Expert interviews
- Field visits
- Surveys
4
Data Analysis
- Quantitative modeling
- Statistical testing
- Validation
5
Insights & Reporting
- Synthesis
- Recommendations
- Visualization
Research Depth
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Historical vs. Forecast Data
Historical (observed)
Forecast (modelled)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansCompetitive Landscape & Porter's Five Forces
Breast Biopsy Market — Competitive Analysis
Threat of New Entrants
The threat of new entrants in the breast biopsy market is moderate. Any company manufacturing breast biopsy is required to accept and abide by the mandatory regulatory standards set by the respective regulatory authorities of a country, such as the United States Food and Drug Administration (FDA), European Medicines Agency (EMA), The Central Drugs Standard Control Organization (CDSCO), and others. However, huge opportunities in the market have encouraged many players to invest in this lucrative market. Moreover, supportive government policies and a rising number of investors have impulse entrepreneurs to enter the handheld surgical device industry. These factors are responsible for minimizing the entry barriers for new players, which can be a major threat to the current companies.
Bargaining Power of Suppliers
The global breast biopsy market suppliers are the developers and manufacturers of breast biopsy such as forceps, retractors, graspers, and others used in various general surgical procedures. The bargaining power of suppliers is a crucial factor in the breast biopsy market and determines the industry's strength. Many suppliers are currently present in the market due to the high demand for breast biopsy and increasing government support. The existing key companies capture significant market share and monitor the costs of breast biopsy. The switching cost of these suppliers is moderate because suppliers tend to enter long-term associations, partnerships, and deals with other handheld surgical device manufacturing companies. Thus, the overall bargaining power of suppliers in the global breast biopsy market is expected to be moderate during the forecast period.
Threat of Substitutes
Breast Biopsy are reliable, cost-effective products such as scalpels, forceps, retractors, and others used in various general surgical procedures. Furthermore, many large and medium-scale companies manufacture different types of products for different application. Some small companies provide their products at low prices to sustain themselves in this highly competitive market. Thus, the overall threat of substitutes in the global breast biopsy market is expected to be moderate-to-low during the forecast period.
Bargaining Power of Buyers
The global breast biopsy market is characterized by the presence of a large number of buyers. The market for breast biopsy is identified as having a significant customer base, considering the increasing number of patients suffering from chronic diseases and the increasing use of products for various biopsy procedures. However, the buyers tend to use the products that have been provided by the top players irrespective of the pricing. Thus, the bargaining power of buyers is expected to be moderate in the global breast biopsy market during the forecast period.
Intensity of Rivalry
The overall degree of competition in the global breast biopsy market is high. The reserved degree of product differentiation among existing players increases the intensity of rivalry in the market. The companies engaged in manufacturing breast biopsy are developing advanced products for differentiating their brand from the competitors. Additionally, many prominent market players are entering into strategic partnerships, co-development activities, and tie-ups with established companies to overcome the competition. Thus, the intensity of rivalry in the global breast biopsy market is expected to be high during the study period.
Quantitative Analysis
Regional Breakdown
Regional market breakdown for Breast Biopsy Market.
Regional Market Size (USD Mn)
Market estimates by geography (2030)
USD Mn
InsightNorth America leads with $406.60M by 2030, while Asia Pacific is projected to grow fastest at a 7.5% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansRegional Market Data
| REGION | 2018 | 2021 | 2030 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $202.80M | $268.50M | $406.60M | 6.0% | 34% |
| Europe | $148.90M | $198.80M | $303.90M | 6.1% | 26% |
| Asia Pacific | $158.70M | $228.90M | $376.50M | 7.5% | 32% |
| Rest of the World | $54.80M | $68.90M | $98.70M | 5.0% | 8% |
| Total | $565.20M | $765.10M | $1.19B | 6.4% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSegment Revenue (2030)
Biopsy Needles
Biopsy Wires
Guidance Systems
Others
Biopsy Tables
0146292437583
Segment Market Share
- Biopsy Needles45%
- Biopsy Wires18%
- Guidance Systems15%
- Others13%
- Biopsy Tables10%
Total Market Size
$1.19B
Market by Segment (2030)
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Biopsy Needles | $529.30M | 6.4% | 89% |
| Biopsy Wires | $214.30M | 6.4% | 66% |
| Guidance Systems | $176.40M | 6.4% | 54% |
| Others | $151.80M | 6.4% | 53% |
| Biopsy Tables | $113.80M | 6.4% | 61% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansEmpower your Business
with InsightsSave over 20% on
with Insights
Save over 20% on
Annual Subscription
See plans for professionals or small and medium businesses.
Analytics
Breast Biopsy Market — Key Findings
Analytical insights on Breast Biopsy Market covering market dynamics, competitive landscape, and strategic outlook.
Key Analytical Findings
The Breast Biopsy Market market is projected to reach $1.19B by 2030, growing at 6.4% CAGR. The Biopsy Needles segment holds the largest share.
Market Drivers
The rising incidence of breast cancer is a significant factor in the market's expansion. The prevalence of breast cancer is significantly rising, raising awareness among people globally to get screened and diagnosed. In order to reduce the occurrence of breast cancer in the population, it is necessary to collect a variety of cumulative data, raise awareness, set up facilities, and treat these patients after a thorough analysis. The two main guidance systems for the accurate detection of breast cancer are mammograms and ultrasounds. Using a variety of modalities, including ultrasound, mammography, and MRI, breast cancer screening helps medical practitioners find breast cancer in a patient. These specialists do breast biopsies for the early detection and diagnosis of breast cancer, assisting patients in receiving the proper care in the event of positive results. The demand for breast biopsy procedures is being driven by the rise in breast cancer incidence among people globally. Thus, it is anticipated that this will accelerate market growth.
Market Opportunities
The main opportunity in the market is a surge in programmes to identify breast cancer in its earliest stages. Many public and private organizations are sponsoring the creation of brand-new, cutting-edge products for breast cancer screening. These cutting-edge technological solutions are anticipated to help provide better solutions and technical tools and enhance patient preventive care. For instance, the European Commission has supported initiatives like B-CAST and BRIDGES. Next-generation sequencing, or BRIDGES, enables the identification of females who have a high risk of developing breast cancer. This will enable such at-risk patients to receive a thorough assessment of their DNA variants or mutations and take the appropriate preventive measures. Breast cancer stratification is available through B-CAST. These techniques are being created so that the likelihood of breast cancer in a person can be precisely identified. Both initiatives aim to advance the way that genetic testing is currently used to assess women's risk of acquiring breast cancer. Hence, chances will be presented for market expansion.
Market Restraints
To ensure that these procedures are carried out only when necessary and with the highest level of safety and accuracy, strict rules may be put in place to restrict the breast biopsy market. These rules may include stringent requirements for patient selection and informed consent, as well as training and certification standards for medical personnel who perform breast biopsies. Regulatory agencies may also set requirements for breast biopsy techniques' precision and dependability and mandate that only the most cutting-edge imaging and biopsy technology be used by service providers. This will guarantee that patients receive the best care and precise diagnoses while perhaps reducing the number of hospitals authorized to do breast biopsies. Overall, while stringent regulations may restrict the market for breast biopsies in terms of the number of practitioners and facilities offering these procedures, they would also make sure that patients receive reliable diagnoses, thereby improving patient outcomes and minimizing the use of unnecessary procedures.
Market Challenges
Radiologists and surgeons use biopsy needle techniques, such as core needle and fine needle procedures, to examine anomalies at a specific spot. Nevertheless, because these treatments entail making cuts and incisions to remove tissue samples, patients may get infected while undergoing them. Reusing biopsy needles raises the risk of infection during these operations in a number of circumstances. Reusing some needles is not advised by healthcare authorities or product makers, although it is still common, particularly in developing nations. Therefore, healthcare professionals and patients may choose other diagnostic techniques for the target illnesses to prevent the risk of infections from these treatments.
Strategic Outlook and Future Directions
The COVID-19 outbreak, which started in China, has had a major impact on the global economy. The outbreak has impacted the global economy in several ways, including industries such as oil & gas, manufacturing, energy, chemicals, and pharmaceuticals. This pandemic has not only caused disruptions in the supply chains of the industrial sector but also influenced the purchasing decisions and spending behavior of the end users. Moreover, the industrial sector has been severely affected as most countries worldwide have imposed lockdown restrictions, which have not only impacted the import & export of goods & services but has also declined the sales of products in the domestic market.
Furthermore, industries such as electrical and electronics, oil & gas, and manufacturing, among others, have either stopped operations completely or have reduced their workforce due to the pandemic and safety of the employees, which has drastically impacted the breast biopsy market. Most companies in the breast biopsy business have seized operations to ensure the safety of employees. However, some companies are operating at minimum capacity to support essential industries.
The pandemic has impacted the breast biopsy market globally. As many businesses came to a halt in the first quarter of FY’2020, manufacturing plants cut output due to declining demand. Furthermore, the breast biopsy producers had to shut down their operations in a few parts of the country due to less demand. Additionally, manufacturers have also been impacted as all the major industries have attempted to contain the virus by shutting down their businesses. These factors have impacted the breast biopsy market globally. On the other hand, the US, China, India, and other key markets in Europe have also witnessed a greater impact on the manufacturing industry due to the global pandemic and the shutdown of manufacturing plants. The demand for breast biopsy across end users has decreased drastically due to the halt in production sites because of COVID-19.
The pandemic has affected the economic environment for a number of businesses around the world. The supply chain in the global market is the key to fulfilling customer demands. As a result of the COVID-19 pandemic, several countries-imposed import and export restrictions. This has also impacted the healthcare industry as many countries rely on other countries for raw material supply. Raw materials required for manufacturing breast biopsy had a shortage due to trade barriers that hampered the market. COVID-19 significantly disrupted the breast biopsy industry in 2020, as the production and supply chain of breast biopsy has been restricted due to the lockdowns. Additionally, due to a change in healthcare priorities and as a precautionary measure to constrain the spread of the COVID-19 virus, several surgeries and procedures were postponed. This led to a significant backlog in the number of surgical procedures performed, thereby affecting the market negatively. In addition, several ambulatory surgical centers had to be shut down due to the huge losses that they had to incur as a result of the COVID-19 pandemic. However, in 2021, hospitals and other settings started performing surgical procedures in full volume and it has helped the market to recover. Significant backlogs in surgical procedures and increasing demand for elective surgeries are further expected to surge the demand for the breast biopsy market.
Breast Biopsy are likely to witness lucrative growth through an anticipated recovery of prices and strategic measures taken by the companies operating in the upstream sector to increase the E&P activities. The ongoing investments by the major players in the industry to enhance breast biopsy is projected to enhance the prices of breast biopsy.
The main target for the companies in this COVID-19 situation would be to provide products to the client base at a minimal price or at least with the same pricing for breast biopsy. This may come as a challenge for the market players as their expenditures are allegedly rising, owing to the COVID-19 pandemic, as sanitization & hygiene standards in the organization, additional benefits are given to the employees keeping in mind the pandemic situation and others increasing the cost. Moreover, due to stricter lockdown measures in several countries, many companies have shifted temporarily to remote working, which has hampered their services.
Market Value by Segment (2030)
Value (USD Mn)
Biopsy Needles
Biopsy Wires
Guidance Systems
Others
Biopsy Tables
Companies
Key companies profiled in Breast Biopsy Market
Profiles of 106 companies operating in the Breast Biopsy Market market, including revenue, employee count, and market positioning where available.
Showing 106 of 106 companies
Planmed Oy
Planmed Oy
Healthcare
Company Headquarters: Finland Founded: 1987 Workforce: The company has employed more than 50 employees. Company Working: Planmed Oy is a Finnish medical technology company that specializes in developing and manufacturing imaging equipment for medical applications. Planmed's product portfolio includes a range of imaging solutions for breast cancer detection and diagnosis, including mammography units and biopsy systems. Planmed also provides a range of services and support for its breast imaging products, including training and education for healthcare professionals, technical support and maintenance services, and research and development of new imaging technologies and techniques.
RevenueN/A
Employees50
Market CapN/A
Founded1986
Finland
Cook Medic
Cook Medical Incorporated
Healthcare
Company Headquarters: United States Founded: 1977 Workforce: The company has employed more than 900 employees in all its facilities. Company Working: Cook Incorporated is a privately held global medical technology company that provides innovative solutions for a range of medical conditions. The company's products and services are used in a variety of medical specialties, including interventional radiology, cardiology, and women's health. Cook Incorporated's breast biopsy products and services are designed to provide accurate and efficient diagnosis of breast cancer, while minimizing patient discomfort and reducing the need for follow-up procedures. The company's innovative technologies enable precise targeting and sampling of breast tissue, as well as automated specimen collection for efficient and accurate diagnosis.
RevenueN/A
Employees900
Market CapN/A
Founded1976
United States
NuVue Ther
NuVue Therapeutics
Healthcare
Company Headquarters: United States Founded: 1999 Workforce: The company has employed 50 to 100 employees in its facility. Company Working: NuVue Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies for the treatment of various forms of cancer. The company's lead product candidate is called NU103, a drug designed to improve the accuracy of breast cancer diagnosis through targeted imaging. NuVue Therapeutics also offers clinical development services to support the development and commercialization of new cancer therapies.
RevenueN/A
Employees100
Market CapN/A
Founded1998
United States
Leica Bios
Leica Biosystems
Healthcare
Company Headquarters: Germany Founded: 1989 Workforce: The company has employed more than 80,000 employees throughout the world. Company Working: Leica Biosystems is a global leader in developing and manufacturing innovative solutions for cancer diagnosis. Their product portfolio includes a range of instruments, reagents, and consumables used in the preparation and analysis of tissue samples for cancer diagnosis and research. One of the products offered by Leica Biosystems is their breast biopsy product, which includes a range of instruments, reagents, and consumables used for breast biopsy procedures. These products help to ensure accurate and efficient collection of breast tissue samples, which can then be analysed for the presence of cancer.
RevenueN/A
Employees80,000
Market CapN/A
Founded1988
Germany
Argon Medi
Argon Medical Devices
Healthcare
Company Headquarters: US Founded: 1972 Workforce: 1000 Company Working: Argon Medical Devices is a global medical technology company that specializes in the development, manufacturing, and marketing of medical devices for interventional procedures. The company has a strong focus on providing innovative, high-quality products to healthcare professionals, and improving patient care. Argon Medical Devices offers a wide range of products, including vascular access devices, biopsy and drainage devices, and peripheral vascular devices. The company's products are used in a variety of procedures, such as hemodialysis, interventional radiology, and oncology. Argon Medical Devices is committed to ensuring that its products are safe, effective, and reliable, and meet the needs of healthcare providers and their patients. Argon Medical Devices' breast biopsy products are designed to improve the accuracy, speed, and safety of breast biopsy procedures, ultimately leading to better patient outcomes. The company has its presence in over 114 countries.
RevenueN/A
Employees1,000
Market CapN/A
Founded1971
US
Hologic In
Hologic Inc.
Healthcare
Company Headquarters: US Founded: 1985 Workforce: 6,705 Company Working: Hologic Inc. is a medical technology company based in Marlborough, Massachusetts, USA. The company specializes in developing and manufacturing diagnostic and surgical products for women's health, including mammography and biopsy systems, cervical cancer screening tests, and other medical devices. Hologic is known for its advanced technologies and innovative solutions that help healthcare providers detect and treat various diseases. Hologic's biopsy device is also known for its patient-friendly features, such as a smaller incision size and reduced pain and discomfort during the procedure. The device is widely used by healthcare providers in both hospitals and outpatient settings, helping to improve patient outcomes and reduce the need for more invasive procedures. Hologic has a significant global presence, with operations in over 50 countries around the world. The company's products are sold in more than 90 countries, and it has manufacturing facilities and research and development centers in multiple locations.
Revenue$2.7B
Employees6,705
Market CapN/A
Founded1984
US
Page 1 of 18
…
Go to page
Powering the world's best teams.
From next-gen startups to established enterprises.
What our clients say
Trusted by forward-thinking businesses
for data-driven intelligence
Noah Malgeri
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Michael Robert
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Bong Lau
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Mark Irwin
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
Jason Lee
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Akif Moroglu
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Noah Malgeri
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Michael Robert
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Bong Lau
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Mark Irwin
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
Jason Lee
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Akif Moroglu
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Breast Biopsy Market
Starting from
$4,950